SPC Gilead Truvada

Gilead successfully defends and enforces its SPC for Truvada


Your contacts

In two recent decisions, the Swiss Federal Patent Court upheld the validity of Gilead’s Supplementary Protection Certificate (SPC) for Truvada®, a combination preparation of tenofovir disoproxil fumarate and emtricitabine used with other HIV-1 medicines to treat HIV-1 infection, and subsequently preliminarily enjoined Teva from distributing its Truvada® generic in Switzerland.

In proceedings on the merits, Teva (or rather Mepha, its Swiss subsidiary) sought a declaration of invalidity of Gilead’s Swiss SPC. It did not attack the validity of the basic patent EP 0 915 894. Neither was it disputed that a generic of Truvada® would infringe the (expired) basic patent and that Gilead’s SPC was therefore valid under the infringement test.

The basic patent explicitly mentions tenofovir disoproxil, but not emtricitabine. Teva argued that Switzerland should abandon the infringement test traditionally employed (BGE 124 III 375 – Fosinopril) in favour of the new ECJ’s case law concerning combination products. Applied to the combination of tenofovir disoproxil and emtricitabine, this would, according to Teva’s point of view, lead to the nullity of the SPC.

The Federal Patent Court sided with Gilead, which argued inter alia that legal certainty – at the time of application of the Swiss SPC in 2006, the ECJ’s Medeva decision (EU:C:2011:773) had not yet issued – demanded that the SPC be judged under the infringement standard. Harmonization of Swiss law with European Union law did not compel adopting the ECJ’s case law after Medeva. While it was correct that the Swiss SPC was introduced to harmonize Swiss law with the (then) relevant European legislation regarding Supplementary Protection Certificates, harmonization was unnecessary because it would not lead to better market access (free movement of goods). Switzerland was not part of the EU regulatory framework for the approval of pharmaceuticals. Drugs approved in Switzerland need separate approval in the EU, and vice-versa. Regulatory law therefore impeded the free movement of pharmaceuticals irrespective of whether SPC law was harmonized.

The court could have left it at this, but it went on to assess whether applying the ECJ’s case law would benefit legal certainty. The court summarizes the various decisions of the ECJ concerning SPCs and concludes that the ECJ’s jurisprudence in this area of law was a “terminological mess” (“terminologisches Durcheinander”). The court also notes that the ECJ’s case law was apparently so unclear that Arnold J, “a renowned expert in the area of SPC law” was forced yet again to submit a question to the ECJ (referring to [2017] EWHC 13 (Pat)). Legal certainty would therefore suffer if Switzerland abandoned the (comparatively easy to apply) infringement test.

Gilead then sought a preliminary injunction prohibiting Teva (Mepha) from distributing its Truvada® generic on the Swiss market. This case presented another interesting first: Gilead’s Swiss SPC describes the combination of tenofovir disoproxil fumarate and emtricitabine as product. Teva’s generic uses the tenofovir disoproxil phosphate salt. Teva argued that the generic was therefore not the same product (Erzeugnis) as the one covered by the SPC.

The Federal Patent Court held that different salt forms of an active pharmaceutical ingredient were the “same product” for purposes of SPC law, provided they have the same pharmacological effect. The definition of the term product reads thus plausible as follows: Emtricitabine plus tenofovir disoproxil fumarate and all derivatives thereof (i.e. in particular all salt forms), to the extent that they have the same pharmacological effects and are covered by the basic patent EP 0 915 894. In the case at hand, it was undisputed that the fumarate and phosphate salt forms of tenofovir disoproxil had the same pharmacological effect, as evidenced by the fact that Teva’s generic had been approved in a simplified marketing authorisation proceeding with Truvada® as reference preparation.

The judgment on the merits in the nullity action is under appeal at the Federal Supreme Court. The proceedings on the merits in the infringement action are ongoing.

A copy of judgment O2017_001 of 3 October 2017 (in English) can be read here and a copy of judgment S2017_006 of 10 October 2017 (in English) can be read here.

Meyerlustenberger Lachenal Ltd. (Michael Ritscher, Simon Holzer and Kilian Schärli) advised Gilead in both proceedings.


Share post



most read


Highlights

MLL Legal

MLL Legal is one of the leading law firms in Switzerland with offices in Zurich, Geneva, Zug, Lausanne, London and Madrid. We advise our clients in all areas of business law and stand out in particular for our first-class industry expertise in technical-innovative specialist areas, but also in regulated industries.

MLL Meyerlustenberger Lachenal Froriep

Newsletter

Much is still unclear in relation to liability questions around AI tools.

Read our latest post about “Liability during the Lifecycle of an AI Tool” and download our white paper.

Show article.

Our Story

MLL Legal is a leading Swiss law firm with a history that dates back to 1885. The firm has grown both organically and by means of strategic mergers, the latest of which took place on 1st July 2021 between Meyerlustenberger Lachenal and FRORIEP.

The merger establishes MLL Legal, a combined new entity as one of the largest commercial law firms in Switzerland with 150 lawyers in four offices in Switzerland and two offices abroad, in London and Madrid serving clients seeking Swiss law advice.

Our firm has a strong international profile and brings together recognised leadership and expertise in all areas of law affecting commerce today, with a focus on high-tech, innovative and regulated sectors. 

About us

Publications

Click here for our latest publications

COVID-19

Read all our legal updates on the impact of COVID-19 for businesses.

COVID-19 Information

Job openings

Looking for a new challenge?

Our talented and ambitious teams are motivated by a common vision to succeed. We value open and straightforward communication accross all levels of the organisation in a supportive working environment.

Job openings

Firm News

Click here for our latest firm news.

Our Team

The regulatory and technological landscape continually require businesses to adapt and evolve.
Our 150+ lawyers are continuously innovating and striving for improvement in everything they do. We embrace new ideas and technologies, combining our wealth of expertise with creative thinking and diligence. With our hands-on approach, we implement viable solutions for the most complex legal challenges.

Our Team.

LexCast – the podcast series by MLL NexGen

Smart legal education on the go. The LexCast hosted by MLL NexGen provides legal insights in a short format that allows listeners to educate themselves on and about legal issues wherever they are and whenever they find the time.

Listen to our podcast series – stay tuned.

MLL Legal on Social Media

Follow us on LinkedIn.